Related Experiment Videos
Use of intracavernosal alprostadil in erectile dysfunction
1Bristol Urological Institute, Southmead Hospital.
Hospital Medicine (London, England : 1998)
|December 16, 1998
Summary
Alprostadil, a prostaglandin E1 injection, is a leading treatment for erectile dysfunction. It shows effectiveness in 70-80% of patients with a favorable side-effect profile.
Area of Science:
- Urology
- Pharmacology
Background:
- Erectile dysfunction (ED) is a common condition affecting many men.
- Vasoactive agents are used for ED investigation and treatment.
Purpose of the Study:
- To highlight Alprostadil as a primary intracorporeal injection for ED.
- To discuss its efficacy and safety profile.
Main Methods:
- Review of Alprostadil's clinical application in ED.
- Analysis of its effectiveness and side-effect data.
Main Results:
- Alprostadil is the most utilized licensed vasoactive agent for ED.
- Effective in 70-80% of treated patients.
- Demonstrates a good side-effect profile.
Conclusions:
- Alprostadil is a well-established and effective treatment for erectile dysfunction.
- Its favorable safety and efficacy make it a preferred choice for intracorporeal injection therapy.